The dsRNA-activated protein kinase PKR is an interferon (IFN)-induced protein that was initially identified and characterized as a translation inhibitor in the antiviral pathway regulated by IFN-=. 1) In the presence of viral dsRNA or PKR activator proteins, PKR is activated via dimerization and autophosphorylation. 2) Once activated, PKR acquires the capacity to phosphorylate the subunit of eukaryotic translation initiation factor eIF2 (eIF2). On viral infection of IFN-treated cells, PKR is activated by viral dsRNA, which leads to the phosphorylation of eIF2. 1) Phosphorylated eIF2 prevents the recycling of initiation factors, which leads to the inhibition of viral and cellular protein synthesis.
Viral factors, such as adenovirus VA RNA, HIV TAR RNA, vaccinia virus E3L, and influenza virus NS1, [3] [4] [5] [6] [7] inhibit the antiviral activity of PKR. Moreover, host factors, such as P58IPK, activated by infection with influenza virus, also inhibit PKR activity. 8) In addition to these antiviral functions, PKR is involved in several intracellular signaling pathways and in apoptosis induced by lipopolysaccharide (LPS), tumor necrosis factor (TNF-), and dsRNA. 9) In addition, PKR has been implicated in other cellular events, including cellular transformation, 10) proliferation, 11, 12) and splicing. 13) Recently, several cellular dsRNA-binding proteins have been identified, including HIV TRBP, 14) NFAR, 15) NFAR-2, 15) ribosomal protein L18, 16) and IL-11-induced nuclear protein C114. 17) All of these proteins bind to PKR and inhibit the activation of PKR. Cellular protein P58IPK prevents dimerization of PKR. 8) Moreover, its function is inhibited by the binding of P52rIPK and Hsp40. 18, 19) In addition, cellular protein activators of PKR, PACT, and RAX (the mouse homolog of PACT) have been identified. 20, 21) Many cellular and viral factors can bind to PKR. In this context, the cellular localization of these regulatory proteins and PKR determine the activation or inactivation sites for the expression of PKR activity. The ratio of cytoplasmic to nuclear PKR is approximately 5:1 in control human cells. 22) Cytoplasmic PKR increases on treatment with IFN, but nuclear PKR does not. The physiological role of nuclear PKR is poorly understood, and the PKR nuclear localization signal has not been identified. To elucidate the mechanism producing the intracellular distribution of PKR protein between the cytoplasm and the nucleus, it is necessary to identify novel proteins that interact with PKR in the cytoplasm and nucleus.
To investigate the interaction of PKR with cellular proteins, we performed immunoblotting with anti-PKR antiserum raised against the N-terminal region of conserved dsRNA motifs, and used immunoprecipitation with anti-PKR peptide antibody raised against synthetic peptides corresponding to the C-terminal region of PKR, which sustains the interaction of PKR with cellular proteins. In a series of co-immunoprecipitation experiments combined with two-dimensional gel electrophoresis, a new PKR-associated protein, designated DRBP-120, was detected in both the cytoplasm and nucleus of y To whom correspondence should be addressed. Tel: +81-19-621-6154; Fax: +81-19-621-6177; E-mail: taira@iwate-u.ac.jp Abbreviations: dsRNA, double-stranded RNA; PKR, double-stranded RNA activated protein kinase; DRBP, double-stranded RNA binding protein; SDS-PAGE, SDS-polyacrylamide gel electrophoresis HeLa cells. DRBP-120 is distinct from reported PKRassociated proteins.
Materials and Methods
Cell culture. HeLa cells were grown in minimum essential medium (Nissui Pharmaceutical, Tokyo) supplemented with 10% newborn bovine serum at 37 C in 5% CO 2 /95% air. Where indicated, HeLa cells were treated with 500 IU/ml of IFN-(Sigma-Aldrich, St. Louis, MO) for 20 h before harvesting.
Antibodies. Anti-PKRn antiserum: The human PKR N-terminal region (PKRn, residues 1-259) was expressed as a glutathione S-transferase (GST)-fusion protein in Escherichia coli and purified using glutathione Sepharose. After cleavage of GST, purified PKRn was injected into a rabbit together with Freund's complete adjuvant to raise polyclonal antisera. Anti-PKR antibody K17 raised against a peptide corresponding to the C-terminal domain of human PKR was purchased from Santa Cruz Biotechnology (Santa Cruz, CA) (Fig. 1A) . Anti-NFAR-2 antiserum: The 20 amino acid residues of the C-terminal of NFAR-2 (QSSQGGYGRNADHSMNYQYR) were conjugated with keyhole limpet hemocyanin and injected into a rabbit together with Freund's complete adjuvant to raise antisera.
Preparation of S10 extract. All the subsequent steps in the preparation procedure were carried out at 4 C. The HeLa cell monolayer was harvested and washed with isotonic buffer (35 mM HEPES-KOH [pH 7.5], 146 mM NaCl, 11 mM glucose) three times. The cells were suspended in one packed-cell volume of hypotonic buffer (10 mM HEPES-KOH [pH 7.5], 15 mM KCl, 1.5 mM magnesium acetate, 6 mM 2-mercaptoethanol [2-ME]) and kept on ice for 10 min before sonication for 30 sec. After sonication, 5/18 packed-cell volume of hypertonic buffer (200 mM HEPES-KOH [pH 7.5], 1.2 M KCl, 50 mM magnesium acetate, 60 mM 2-ME) was added. The cell suspension was first centrifuged at 1;000 Â g for 5 min and then at 10;000 Â g for 10 min. The supernatant was designated the S10 extract.
dsRNA-activated protein kinase assay. The S10 extract (20 ml) was mixed with 20 ml of a 50% slurry of poly (I-C) Sepharose (Amersham Pharmacia Biotech, NJ), and rotated at room temperature for 90 min. binding buffer (20 mM HEPES-KOH [pH 7.5], 150 mM KCl, 5 mM magnesium acetate, 1 mM dithiothreitol, 1 mM phenylmethanesulfonylfluoride [PMSF], 0.5% NP-40, 10% glycerol) three times and 20 ml of SDS sample buffer (125 mM Tris-HCl [pH 6.8], 4.6% SDS, 10% 2-ME, 20% glycerol, 0.02% bromophenol blue) were added to the Sepharose and then boiled at 100 C for 5 min. The poly (I-C) bound and labeled proteins were resolved by 8% SDS-PAGE. The gel was fixed, dried, and exposed to X-ray film for autoradiography.
dsRNA binding assay. The S10 extract (20 ml) was diluted five-fold in binding buffer, and an equal volume of a 50% slurry of poly (I-C) Sepharose was added and rotated at room temperature for 2 h. After centrifugation, the poly (I-C) Sepharose was recovered and the supernatant, designated the nonbinding fraction, was recovered. The poly (I-C) Sepharose was washed four times by suspending it in a five-fold volume of binding buffer and centrifuging it at 10;000 Â g. The supernatant was designated the wash fraction. The poly (I-C) Sepharose binding proteins were eluted batch-wise with binding buffer containing 3, 4, 5, 6, 7, or 8 M urea, and the fractions were designated the binding fraction. The fractions were mixed with an equal volume of SDS sample buffer and kept at room temperature for 30 min. The proteins were detected by immunoblotting with anti-PKRn antiserum, as described previously.
23)
Cell fractionation and cell lysate. HeLa cell fractionation was performed according to the procedure described in Galabru et al. (1987) . 24) Preparation of the nuclear fraction was confirmed by anti-NFAR2 antiserum. All subsequent steps in the preparation procedure were carried out at 4 C. HeLa cells were harvested and washed with isotonic buffer three times. The cells were suspended in 200 ml of lysis buffer (20 mM Tris-HCl [pH 7.6], 50 mM KCl, 400 mM NaCl, 5 mM 2-ME, 1% TritonX-100, 100 units/ml aprotinin, 0.2 mM PMSF, 20% glycerol) and kept on ice for 10 min. The cells were sonicated and centrifuged at 10;000 Â g for 10 min; the supernatant was collected and designated the cell lysate.
Co-immunoprecipitation. The S10 extract (20 ml) was diluted ten-fold with hypotonic buffer (10 mM HEPES-KOH [pH 7.5], 15 mM KCl, 1.5 mM magnesium acetate, 6 mM 2-ME), or the nuclear lysate (20 ml) was diluted ten-fold with lysis buffer, and 3 ml of anti-PKR antibody K17 was added, and then the mixture was rotated at 4 C for 1 h. Twenty-five ml of a 50% slurry of protein A Sepharose was added to the diluted S10 extract or nuclear lysate. The mixture was rotated at 4 C for 1 h, and the immune complexes adsorbed on the protein A Sepharose were washed three times in 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM EDTA, 0.1% NP-40, and 0.02% NaN 3 , and then denatured in SDS sample buffer by boiling for 3 min. The samples were analyzed by 8% SDS-PAGE, followed by immunoblotting.
Results

Detection and characterization of DRBP-120
To detect and characterize novel proteins that can interact with PKR, we performed immunoblotting with anti-PKR antibodies (Fig. 1A) . Most PKR-associated proteins, including PKR regulators and substrates, are dsRNA-binding proteins that contain potential RNA binding motifs. Anti-PKRn antiserum against the PKR N-terminal region (PKRn, residues 1-259) containing two dsRNA binding motifs was prepared and used to detect PKR and other RNA-binding proteins in HeLa cells treated with IFN. As shown in Fig. 1B , immunoblotting of HeLa cell extracts with anti-PKRn antiserum detected PKR proteins as a major 68-kDa band, a minor 72-kDa band, and a 120-kDa band in HeLa cells (lanes 1 and 2). The 68-kDa band increased in IFN--treated cells (lanes 2 and 4), while the 120-kDa band did not increase with the IFN treatment. PKR expression at a level similar to the 68-kDa band was detected with anti-PKR antibody K17 against the C-terminal peptide, while the 72-and 120-kDa bands were not detected (lanes 3 and 4). These minor bands were not detected even when the bands of PKR were detected at the same level as that of 68-kDa in lanes 1 and 2. These observations indicate that the 120-kDa band detected with anti-PKRn contains a domain with a dsRNA-binding motif similar to that of PKR, and we designated it DRBP-120 (double-stranded RNA binding protein 120-kDa). The 72-kDa minor band was identified as a keratin-like protein by mass spectrometry and amino acid sequence determination (data not shown).
To demonstrate the interaction of DRBP-120 with dsRNA and its phosphorylation, HeLa-cell extracts were incubated in the presence of poly (I-C) Sepharose and [-32 P]-ATP. As shown in Fig. 1B (lane P), dsRNA bound and phosphorylated the proteins of the 68-and 120-kDa bands corresponding to PKR and DRBP-120 respectively, indicating that both PKR and DRBP-120 are dsRNA-binding proteins that are phosphorylated when incubated with dsRNA and ATP.
Binding capacity of DRBP-120 to dsRNA
To demonstrate that the DRBP-120 protein interacts with dsRNA, poly (I-C) Sepharose was used to recover endogenous DRBP-120 from S10 extracts of HeLa cells, as described in ''Materials and Methods.'' The proteins bound to poly (I-C) Sepharose were eluted at various urea concentrations, electrophoresed, and immunoblotted using anti-PKRn antiserum. The elution profiles of S10 are shown in Fig. 2 . PKR was detected mainly in fractions 8-11, the binding fractions, and DRBP-120 was detected mainly in fractions 6-9. In contrast, the keratin-like 72-kDa protein was detected in fractions 1-3, which were designated the wash fraction.
Interaction between DRBP-120 and PKR
Interactions between some dsRNA-binding family members and their homologs have been observed via dsRNA or protein-protein interactions. 15, 17, 20, 25) To examine the interactions between DRBP-120 and PKR, we used co-immunoprecipitation assays to define the interaction between DRBP-120 and PKR and to determine the contribution of dsRNA-binding to the interaction. S10 extract of HeLa cells was co-immunoprecipitated with anti-PKR antiserum K17. The immunoprecipitate was resolved by gel electrophoresis and detected by immunoblotting with anti-PKRn antiserum. These ''IP-Western'' assays revealed that DRBP-120 and PKR were immunoprecipitated with cognate antibody (Fig. 3A, lanes 2-4) , but not with a control antibody (data not shown). Furthermore, co-immunoprecipitated DRBP-120 increased after the S10 extracts were preincubated with poly (I-C) and ATP before immunoprecipitation (Fig. 3A, lanes 3 and 4) . This suggests that the autophosphorylated PKR induced by pre-incubation with poly (I-C) and ATP increased the binding activity of these two proteins, or that the interaction between DRBP-120 and PKR was mediated via the poly (I-C) molecule.
Intracellular distribution of DRBP-120
PKR is predominantly found in the cytoplasm, where it is closely associated with ribosomes, although some PKR resides in the nucleus. To examine the intercellular distributions of PKR and DRBP-120, HeLa cells were fractionated into nuclear lysate (N) and cytoplasmic (C) fractions, and the cytoplasmic fraction was further fractionated into a 10;000 Â g pellet fraction (P10), a 100;000 Â g pellet fraction (P100), and a 100;000 Â g supernatant fraction (S100). These fractions were subjected to immunoblotting with anti-PKRn antiserum (Fig. 3B) . PKR was detected equally in the cytoplasmic S100 and P100 fractions and the nuclear extract, while most of the DRBP-120 was detected in the nuclear lysate, with some in P100. These results indicate that PKR and DRBP-120 are distributed in the cytoplasm and the nucleus in different ratios.
To determine whether DRBP-120 and PKR interact in the nucleus, the nuclear lysate from HeLa cells was used for the ''IP-Western'' assay, as described above. As shown in Fig. 3C , DRBP-120 was co-immunoprecipitated with PKR in the nuclear lysate. DRBP-120 was also co-immunoprecipitated with PKR in the cytoplasmic fraction (data not shown). Co-immunoprecipitated DRBP-120 in the nuclear lysate increased following Immunoprecipitation of S10 extract with anti-PKR antibody K17 (panel A, IP+, lanes 2-4), as described in ''Materials and Methods.'' Lane 1 contained the S10 extract. The S10 extract was incubated (Incubate+, lanes 3 and 4) with 1 mM of ATP and without (poly (I-C) À, lane 3) or with (poly (I-C) +, lane 4) 10 mg/ml of poly (I-C) at 30 C for 20 min. HeLa cells were fractionated into the cytoplasmic fraction (C), nuclear lysate (N), 10;000 Â g pellet fraction (P10), 100;000 Â g supernatant fraction (S100), and 100;000 Â g pellet fraction (P100). These fractions were subjected to immunoblotting (panel B). Immunoprecipitation of the nuclear lysate with anti-PKR antibody K17 (panel C, lanes 2-4), as described in ''Materials and Methods.'' Lane 1 contained the nuclear lysate. The nuclear lysate was incubated (Incubate+, lanes 3 and 4) with 1 mM of ATP and without (poly (I-C) À, lane 3) or with (poly (I-C) +, lane 4) 10 mg/ ml of poly (I-C) at 30 C for 20 min.
pre-incubation with poly (I-C) and ATP (lanes 3 and 4), as observed in the S10 fraction (Fig. 3A) . This also suggests that autophosphorylated PKR increased the binding activity of these two proteins in the nucleus.
Characterization of two dsRNA binding proteins: DRBP-120 and NFAR-2
Recent data have revealed that several cellular proteins interact with PKR. 8, [14] [15] [16] [17] 20, 21, 25, 26) Among these proteins, the 110-kDa NFAR-2 protein that functions in mRNA processing and interacts with dsRNA is similar to DRBP-120 with respect to its molecular weight, dsRNA-binding property, and intercellular distribution. To determine whether DRBP-120 and NFAR-2 are the same protein, the S10 extract of HeLa cells was coimmunoprecipitated with anti-PKR antibody K17 and immunoblotted with anti-PKRn (lane 2) or anti-NFAR-2 (lane 4), as shown in Fig. 4A . NFAR-2 migrated to a slightly lower position than the 120-kDa DRBP-120 protein. The difference between these two proteins was confirmed by two-dimensional electrophoresis analyzed by immunoblotting with anti-PKRn (Fig. 4B, upper  panel) or anti-NFAR-2 (lower panel). DRBP-120 was detected at a more acidic position than PKR, whereas NFAR-2 was detected at a more basic position than PKR, based on the pI of PKR (pI ¼ 8:57) and NFAR-2 (pI ¼ 8:83). These results indicate that DRBP-120 is distinct from NFAR-2. The other PKR-associated proteins, such as NFAR-1, TARB, and PACT, have a molecular weight lower than 110-kDa, and hence DRBP-120 is also distinct from these proteins. RNAspecific adenosine deaminase 1 (ADAR1) is not a PKRassociated protein, but an amino-terminally truncated 110-kDa form of this protein is similar to DRBP-120 in molecular weight, the dsRNA-binding property, and intracellular distribution, 27) but the pI of the 110-kDa form of ADAR1 (pI ¼ 8:72) is more basic than that of PKR. Hence, DRBP-120 and the 110-kDa form of ADAR1 are different proteins.
Discussion
PKR is a cellular protein kinase that regulates a diverse array of biological responses and is a component of the antiviral machinery induced by IFN.
1) It is also involved in regulating cell proliferation, differentiation, apoptosis, and signaling, and is activated by cellular stresses, making it an important regulator of the stress response. 28) Since typical dsRNA is not present in cells in the absence of viral infection, the cellular proteins associated with PKR are thought to initiate the activation and inactivation of PKR, resulting in the induction of proliferation and differentiation. Cellular dsRNAbinding proteins such as TRBP, NFAR (DRBP76, NF90), and NFAR-2 (NF110, ILF3) bind to PKR via their dsRNA-binding motif and inhibit the activation of PKR, 14, 15, 25, 26) while heterodimerization of the PKR activator (PACT) with PKR is mediated via dsRNA binding motifs, but is independent of dsRNA. 20) In this study, immunoblotting with anti-PKRn containing two copies of evolutionarily conserved dsRNA motifs would detect the cellular proteins that interact with PKR. The 120-kDa protein (DRBP-120) was found by immunoblotting. The amount of DRBP-120 co-immunoprecipitated by anti-PKR antibody K17 increased after incubation with ATP and dsRNA, possibly in response to autophosphorylation of PKR, as compared to the controls (Fig. 3A, C) . As shown in Fig. 1B , a dsRNAbinding protein with a molecular mass of 120-kDa was phosphorylated in the S10 extracts with [-32 P]-ATP, suggesting that the phosphorylated 120-kDa protein is DRBP-120; it might be phosphorylated by PKR either directly or indirectly. Furthermore, co-immunoprecipitation of DRBP-120 was observed without the addition 3) were then subjected to SDS-PAGE, followed by immunoblotting with anti-PKRn antiserum or anti-NRAR-2 antiserum. The total cell extract from HeLa cells was separated using two-dimensional gel electrophoresis according to the method of O'Farrell et al., 31) except that the HeLa cells were fixed with 10% TCA before undergoing nonequilibrium pH gradient electrophoresis (NEPHGE) in the first dimension (panel B). The separated spots were analyzed by immunoblotting with anti-PKRn antiserum (IB: Anti-PKRn) or anti-NFAR-2 antiserum (Anti-NFAR-2). The spots where DRBP-120, NFAR-2, keratin-like protein (72 kDa), and PKR were detected are indicated by arrows. PKR was detected as multiple spots due to its phosphorylation states.
of dsRNA, also suggesting that PKR and DRBP-120 associate via a protein-protein interaction via the dsRNA-binding motifs, as with PACT. 20) Approximately 80% of PKR is present in the cytoplasm, while 20% exists in the nucleus. 22) The level of cytoplasmic PKR was elevated in IFN-treated cells, while the level of nuclear PKR did not change. PKR was translocated into the nuclei of cells treated with an agent that damages DNA. 29) Moreover, nuclear PKR might be involved in splicing the mRNA precursor of TNF-. 13) This implies that the subcellular localization of PKR plays a role in cell growth and differentiation, while the functional role of nuclear PKR is largely unknown. Our findings suggest that nuclear PKR interacts with DRBP-120, as shown in the co-immunoprecipitation of the nuclear extracts (Fig. 3C) . The PKR nuclear localization signal was not identified, while leucine-rich nuclear export signal-like sequences were identified in PKR. 30) Although the mechanisms of the nuclear import and export of PKR remain unclear, the translocation of PKR to the nucleus might be affected by several PKR-associated proteins, such as DRBP-120, which exists in both the cytoplasm and the nucleus and might interact with PKR in both fractions. Nuclear export signal-like sequences might regulate the export of nuclear PKR via the binding of DRBP-120 to these sequences.
To further elucidate the role of DRBP-120 interaction with PKR during the many physiological activities of PKR, further studies on the molecular structure and function of DRBP-120 are currently in progress.
